[摘要] 目的：探讨吉非替尼治疗难治性晚期非小细胞肺癌的疗效和不良反应。方法：选择晚期非小细胞肺癌患者21例，给予吉非替尼250 mg/d口服，评价其临床疗效。结果：总的疾病控制率为52.4%，患者中位生存期为272 d。结论：吉非替尼可改善晚期非小细胞肺癌患者的临床症状和生活质量，且耐受好。

    [关键词] 吉非替尼；晚期非小细胞肺癌；靶向治疗

    [中图分类号] R734.2[文献标识码] B[文章编号] 1673-7210(2010)11(c)-133-02

    Efficacy of Gefitinib in the treatment of 21 patients with advanced non-small-cell lung cancer

    ZHANG Chuanhong, WANG Yuhong

    (Hospital of Traditional Chinese Medicine of Zhenjiang City, Jiangsu Province, Zhenjiang 212003, China)

    [Abstract] objective: To study the anti-tumor effect and toxicity of Gefitinib in the treatment of patients with advanced non-small-cell lung cancer(NSCLC). Methods: 21 advanced NSCLC patients were treated with Gefitinib orally 250 mg once per day. The response was evaluated. Results: The disease controlling rate was 52.4%. The median survival time was 272 days. Conclusions: Gefitinib may improve their symptoms and quality of life. It is tolerated by the patients with advanced NSCLC.

    [Key words] Gefitinib; Non-small-cell lung cancer; Target therapy

    原发性支气管肺癌(简称肺癌)是当今世界各国严重危害人类生命的常见的恶性肿瘤 ......